Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks. I appreciate it. I confirmed with CFO. Have a great day.
What’s the strike price on the DMTKW warrants? I know they expire 2024 but can find a strike?
Exactly. Who in their right mind would buy this offering.
After a RS the stock usually continues to drop. Maybe a chance to regain some $$ with some low risk slightly OTM puts.
IMO.
Agreed. It’s criminal that did a cap raise in sept.
Agreed they’re not leaving unless something else that is bad will be announced. Solid guess would be a hold.
Or they realize the people running this show are complete morons and know it will never make it to the finish line so they’re cutting their losses. This seems more plausible.
Please. Give it a rest already. Company is sunk. Amgen wouldn’t leave it the data was promising
Zol. They have I believe to about 4/19/2019 to get over a buck. Do you expect NEO by then to get them over the hump or aim2cerv partner/update. Curious.
Until a reverse split. I’ve seen time and time again a stock that experiences a reverse split is shorted right away. I’d wait till after that short plays out until I’d buy.IMO.
If he wasn’t sure expecting this, than he is a bigger moron than I thought and has no business being a CEO. The warrant kicker was a dead giveaway. Everyone on the board here knew it was going to be delisted and then a reverse split. I said that the day of the announcement.
Anton heave any idea when we will see some NEO results? Mid to late 2019 or earlier?
Berlin@advaxis.com
Why would warrants expiring have anything to do with releasing good news? The warrants being exercised helps the company’s cash position - no one else. That makes zero sense.
They’re not paying a dime for NEO. Amgen coveting all costs. Check your research.
Why sell at this point just ride it out but a certain group of you spin every little thing as it’s great. This company presently is a hot mess end of story. I’ve written this off as a loss that’s why I hardly post.
It’s a phase one company - again and it’s years out again for a third time.
Say it like it is stop sugar coating everything like deals are right around the corner etc. there are no deals in the near term end of story or there wouldn’t be dilution with a warrant kicker because no institutions will invest in this garbage presently. That’s why they’re warrants. The company is grasping at straws for new retail investors and enticing investors with warrants. Plain and simple. It’s going sub 1 and will have to do a reverse split more than likely.
Fine? There is nothing is his pedigree that denotes he knows what he’s doing. What we do know there is no deal for hot to date. Meaning there is No / to minimal interest. If there was interest then a deal would be offered and accepted. This is sunk until NEO results. the SP will languish and most likely be split - in the wrong way.
If NEO results good then up we move if not game over. This BOD couldn’t F this up anymore if they wanted too.
Agreed no where near a deal or it’s not worth much as NEO is the big ticket.
Crazy. This company is sunk for now. Wait till after reverse split. No way it survives above a buck
Reverse split I meant. Auto correct - boo
Reverse a lot on deck. Nuts to buy this crap now
What a horse shit company!!
We’ve been hearing every month for years that OPEX was the reason for suppression. Warrants have nothing to do with it. We need material news. In fact warrants imo have less to do with it since shareholders didn’t write them and get the premium.
Tweet my Petit. Just now.
Generating T cells against neoantigens. The common link between the most successful immunotherapy of solid tumors, including TILs and checkpoint inhibitors, and the forte of Advaxis personal neoantigen, and shared hotsot neoantigens targeted therapies. https://t.co/FRBGyaoAa5
— Robert Petit (@RGPetit2) July 12, 2018
Question? Is there a point where Amgen comes in and saves the day and infuses ash because they are excited about NEO? Or do they let the company go bankrupt
I’d wait. I’m not even expecting a dead cat bounce. Needs a deal by end of summer or it’s gonna be delisted at this rate. Which means a 30/1 reverse split.
Thanks James. Much appreciated.
That’s for the clarification. I guess she meant clinical as you said.
That’s even more alarming as she doesn’t even understand where the company is at. Jesus Christ
I agree with you that Amgen licensed early but her email does state that the preclinical data will be avail at the end of next year.
Correct me if I’m wrong but Amgen licensed before any IND so hopefully a hot deal or two can be landed by late fall since IND filed.
Advaxis would consider partnering one or more assets from the HOT program if the deal made sense. We have more than 10 HOT assets identified, and we have plans to bring 4 forward by the end of 2019. If a partnership would allow for more of the HOT assets to go into the clinic more quickly, and the financial terms also made sense, then we would find a partnership to be worthwhile. Bear in mind that the program is very early, and we will not have any early, preliminary data from the first HOT asset (NSCLC) until the end of 2019, which will be with a small number of patients.
Details of our discussions will not be made public.
Best regards,
Ranya
Here’s her responses for all to interpret:
We have said that we are actively seeking a partner for the US and EU. We will update publicly if and when we secure a partnership. We have also said we have a limited time period by which we need the partner or we will wind down the AIM2CERV study.
We will look to raise cash as needed. We have also reduced the annual burn to about $50M. With a new CFO, raising and preserving cash is a key priority.
Ranya
I just posed the question to Ranya today. She responded as indicated before they have a limited timeframe to secure a partnership or it will be shutdown. It appears the timeframe is months as she discussed the reduction in cash burn and new CFO main concern is preserving n raising capital. Personally I believe it’s a sales tactic to the likes of Merck , BMY etc. in other words we’re going NEO & HOT unless you buck up this year for AXAL.
They should roll AXAL and HOT together but I got the feeling that they haven’t scratched the surface on any Hot deals. As she stated HOT is in the “very early stages and won’t have pre-clinical data until end of 2019. “
Nepotism Mayes
That’s debatable. It could be a way for us to look for some positive. They could believe in NEO but that’s a ways away. What has the management and BOD done that would instill an ounce of confidence in anyone? This company has been run by clowns for the past 10 years. No one has had a clue where to direct energy and resources.
That being said I do like what Ken has done thus far reducing headcount and focus on what appears to be our only hope - NEO and possibly HOT. IMO
Russel rebalance most likely. Black rock has mainly index funds
What’s the point at a buck
Quite honestly that would be a horrible strategy IMO considering we are running on fumes from a cash standpoint.
I believe the scenario that there isn’t much interest is more plausible or terrible negotiating skills on ADXS part, considering what transpired sinceDOC departure and the direction the company was run.
Hoping Ken is going to pull a rabbit out of his hat.
What partner? No one wants to partner with upfront cash as of now.
It appears hot can’t locate a partner or it would’ve been announced today.
NEO is the biggest asset and it’s gone. Hope for excellent NEO results for an Increase in SP. Gonna be years though.
This is sunk for now. . Reverse split and dilution almost a certainty
Basically a preclinical again. Probably the biggest bunch of morons ran this company for years.
The Russell rebalance is gonna hurt. Especially with blackrock. ( index funds)